![Sylvain Chemtob](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sylvain Chemtob
Corporate Officer/Principal at University of Montréal
Sylvain Chemtob active positions
Companies | Position | Start | End |
---|---|---|---|
University of Montréal | Corporate Officer/Principal | 09/07/2009 | - |
McGill University | Corporate Officer/Principal | 16/04/2010 | - |
Career history of Sylvain Chemtob
Former positions of Sylvain Chemtob
Companies | Position | Start | End |
---|---|---|---|
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Chief Tech/Sci/R&D Officer | 09/07/2009 | 09/09/2013 |
Founder | 16/04/2010 | 09/09/2013 |
Statistics
International
Canada | 4 |
Operational
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectoral
Consumer Services | 3 |
Distribution Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
- Stock Market
- Insiders
- Sylvain Chemtob
- Experience